Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMUXNYSE:MBXNASDAQ:RVNCNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMUXImmunic$0.87-1.7%$0.95$0.56▼$2.11$83.36M1.48875,014 shs932,861 shsMBXMBX Biosciences$10.94-4.5%$10.09$4.81▼$27.50$365.66MN/A250,831 shs101,168 shsRVNCRevance Therapeutics$3.65$3.65$2.30▼$6.65$381.02M0.93.44 million shsN/AVERVVerve Therapeutics$6.39$4.62$2.86▼$9.31$569.62M1.671.97 million shs2.03 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMUXImmunic+2.08%+21.21%-12.35%-23.68%-28.02%MBXMBX Biosciences+0.79%-16.18%+3.15%+21.94%+1,144,999,900.00%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+33.21%VERVVerve Therapeutics+4.75%+32.02%+51.06%-0.47%+19.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMUXImmunic3.1902 of 5 stars3.63.00.00.03.32.50.6MBXMBX Biosciences1.968 of 5 stars3.50.00.00.00.03.30.6RVNCRevance Therapeutics2.5274 of 5 stars3.10.00.04.70.01.70.6VERVVerve Therapeutics2.5381 of 5 stars3.52.00.00.01.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMUXImmunic 3.25Buy$11.601,233.33% UpsideMBXMBX Biosciences 3.00Buy$37.50242.78% UpsideRVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideVERVVerve Therapeutics 3.00Buy$25.75302.97% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, RVNC, VERV, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMUXImmunicN/AN/AN/AN/A$0.64 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ARVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11VERVVerve Therapeutics$59.61M9.56N/AN/A$7.31 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%8/6/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ARVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%8/14/2025 (Estimated)Latest IMUX, RVNC, VERV, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMUXImmunicN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMUXImmunicN/A2.712.71MBXMBX BiosciencesN/AN/AN/ARVNCRevance TherapeuticsN/A4.123.05VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMUXImmunic51.82%MBXMBX BiosciencesN/ARVNCRevance Therapeutics97.70%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipIMUXImmunic3.00%MBXMBX Biosciences52.19%RVNCRevance Therapeutics5.10%VERVVerve Therapeutics19.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMUXImmunic7095.82 million87.38 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/ARVNCRevance Therapeutics500104.39 million99.07 millionOptionableVERVVerve Therapeutics11089.14 million68.32 millionOptionableIMUX, RVNC, VERV, and MBX HeadlinesRecent News About These CompaniesBrokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $25.75June 11 at 1:05 AM | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up - What's Next?June 9 at 12:46 PM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Buy" by AnalystsJune 8 at 5:17 AM | marketbeat.comVerve Therapeutics (VERV) Just Reclaimed the 200-Day Moving AverageJune 6, 2025 | zacks.comVerve Therapeutics (NASDAQ:VERV) Trading 10.1% Higher - Time to Buy?June 5, 2025 | marketbeat.comWall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?June 5, 2025 | zacks.comPublic Employees Retirement System of Ohio Purchases 47,656 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)June 5, 2025 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comBank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Has $1.65 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)May 31, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Two Sigma Investments LPMay 31, 2025 | marketbeat.comNuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 31, 2025 | marketbeat.comHeart Disease Could Be a Goner When These New Drugs ArriveMay 29, 2025 | msn.comVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comExperimental drug promising to bring down bad cholesterol by up to 69% completes early stage trialMay 26, 2025 | theprint.inVerve Therapeutics, Inc. (NASDAQ:VERV) Position Lessened by Rafferty Asset Management LLCMay 25, 2025 | marketbeat.comNorthern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)May 25, 2025 | marketbeat.comWall Street Zen Upgrades Verve Therapeutics (NASDAQ:VERV) to "Hold"May 24, 2025 | marketbeat.comGroundbreaking treatment for bad cholesterol on the horizon? This single-use drug shows some promiseMay 24, 2025 | cnbctv18.comStrokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.May 23, 2025 | msn.comHC Wainwright Has Optimistic Outlook of VERV FY2025 EarningsMay 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, RVNC, VERV, and MBX Company DescriptionsImmunic NASDAQ:IMUX$0.87 -0.02 (-1.73%) Closing price 04:00 PM EasternExtended Trading$0.88 +0.01 (+1.15%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.MBX Biosciences NYSE:MBX$10.94 -0.51 (-4.45%) Closing price 04:00 PM EasternExtended Trading$10.94 0.00 (0.00%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Revance Therapeutics NASDAQ:RVNC$3.65 0.00 (0.00%) As of 02/6/2025Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Verve Therapeutics NASDAQ:VERV$6.39 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.40 +0.01 (+0.17%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Will Warner Bros. Discovery’s Split Produce Double the Upside? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
